“Optimizing the prevention of pneumococcal disease in children and adults”

Pneumococcal conjugate vaccines have now been used in children for 20 years. However, a large burden of disease remains, particularly in adults and in low income settings. Key questions remain about which age groups should be targeted with existing vaccines and how to best deploy next-generation vaccines that will become available in the next few years. We will discuss the key roles of transmission and serotype replacement in influencing these patterns.